Abstract
The third-generation aromatase inhibitors are an important class of drugs for use in adjuvant therapy for postmenopausal women with resected estrogen receptor positive breast cancer. Multiple large prospective randomized trials have established their value in this setting and provided guidance for their use in clinical management. This review will outline the trials that have provided evidence on the value of the aromatase inhibitors in the adjuvant setting as well as the ongoing trials that will expand our knowledge of how to use them most effectively.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 765-767 |
| Number of pages | 3 |
| Journal | Steroids |
| Volume | 76 |
| Issue number | 8 |
| DOIs | |
| State | Published - Jul 2011 |
Keywords
- Adjuvant
- Anastrozole
- Aromatase inhibitors
- Clinical trials
- Exemestane
- Letrozole
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Endocrinology
- Pharmacology
- Clinical Biochemistry
- Organic Chemistry